Warburg effect, one of the hallmarks for cancer cells, is characterized by metabolic switch from mitochondrial oxidative phosphorylation to aerobic glycolysis. In recent years, increased expression level of pyruvate kinase M2 (PKM2) has been found to be the culprit of enhanced aerobic glycolysis in cancer cells. However, there is no agent inhibiting aerobic glycolysis by targeting PKM2. In this study, we found that Oleanolic acid (OA) induced a switch from PKM2 to PKM1, and consistently, abrogated Warburg effect in cancer cells. Suppression of aerobic glycolysis by OA is mediated by PKM2/PKM1 switch. Furthermore, mTOR signaling was found to be inactivated in OA-treated cancer cells, and mTOR inhibition is required for the effect of OA on PKM2/PKM1 switch. Decreased expression of c-Myc-dependent hnRNPA1 and hnRNPA1 was responsible for OA-induced switch between PKM isoforms. Collectively, we identified that OA is an antitumor compound that suppresses aerobic glycolysis in cancer cells and there is potential that PKM2 may be developed as an important target in aerobic glycolysis pathway for developing novel anticancer agents.
References
[1]
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57–70. doi: 10.1016/s0092-8674(00)81683-9
[2]
Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891–899. doi: 10.1038/nrc1478
[3]
David CJ, Chen M, Assanah M, Canoll P, Manley JL (2010) HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463: 364–368. doi: 10.1038/nature08697
[4]
Brinck U, Eigenbrodt E, Oehmke M, Mazurek S, Fischer G (1994) L- and M2-pyruvate kinase expression in renal cell carcinomas and their metastases. Virchows Arch 424: 177–185. doi: 10.1007/bf00193498
[5]
Luo W, Semenza GL (2012) Emerging roles of PKM2 in cell metabolism and cancer progression. Trends Endocrinol Metab 23: 560–566. doi: 10.1016/j.tem.2012.06.010
[6]
Parnell KM, Foulks JM, Nix RN, Clifford A, Bullough J, et al.. (2013) Pharmacological activation of PKM2 slows lung tumor xenograft growth. Mol Cancer Ther.
[7]
Wei J, Liu M, Liu H, Wang H, Wang F, et al.. (2012) Oleanolic acid arrests cell cycle and induces apoptosis via ROS-mediated mitochondrial depolarization and lysosomal membrane permeabilization in human pancreatic cancer cells. J Appl Toxicol.
[8]
Guo G, Yao W, Zhang Q, Bo Y (2013) Oleanolic Acid Suppresses Migration and Invasion of Malignant Glioma Cells by Inactivating MAPK/ERK Signaling Pathway. PLoS One 8: e72079. doi: 10.1371/journal.pone.0072079
[9]
Sun Q, Chen X, Ma J, Peng H, Wang F, et al. (2011) Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci U S A 108: 4129–4134. doi: 10.1073/pnas.1014769108
Cerella C, Radogna F, Dicato M, Diederich M (2013) Natural compounds as regulators of the cancer cell metabolism. Int J Cell Biol 2013: 639401. doi: 10.1155/2013/639401
[12]
Datta S, Li J, Mahdi F, Jekabsons MB, Nagle DG, et al. (2012) Glycolysis inhibitor screening identifies the bis-geranylacylphloroglucinol protonophore moronone from Moronobea coccinea. J Nat Prod 75: 2216–2222. doi: 10.1021/np300711e
[13]
Wang Z, Wang D, Han S, Wang N, Mo F, et al. (2013) Bioactivity-guided identification and cell signaling technology to delineate the lactate dehydrogenase A inhibition effects of Spatholobus suberectus on breast cancer. PLoS One 8: e56631. doi: 10.1371/journal.pone.0056631
[14]
Vaughan RA, Garcia-Smith R, Dorsey J, Griffith JK, Bisoffi M, et al. (2013) Tumor necrosis factor alpha induces Warburg-like metabolism and is reversed by anti-inflammatory curcumin in breast epithelial cells. Int J Cancer 133: 2504–2510. doi: 10.1002/ijc.28264
[15]
Wang Z, Wang N, Chen J, Shen J (2012) Emerging glycolysis targeting and drug discovery from chinese medicine in cancer therapy. Evid Based Complement Alternat Med 2012: 873175. doi: 10.1155/2012/873175
[16]
Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9–22. doi: 10.1016/j.ccr.2007.05.008
[17]
Zhang C, Awasthi N, Schwarz MA, Schwarz RE (2013) The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer. Int J Oncol 43: 1627–1635. doi: 10.3892/ijo.2013.2099
[18]
Neri LM, Cani A, Martelli AM, Simioni C, Junghanss C, et al.. (2013) Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. Leukemia.
[19]
Yothaisong S, Dokduang H, Techasen A, Namwat N, Yongvanit P, et al.. (2013) Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. Tumour Biol.
[20]
Li W, Wang J, Chen QD, Qian X, Li Q, et al. (2013) Insulin promotes glucose consumption via regulation of miR-99a/mTOR/PKM2 pathway. PLoS One 8: e64924. doi: 10.1371/journal.pone.0064924
[21]
Iqbal MA, Siddiqui FA, Gupta V, Chattopadhyay S, Gopinath P, et al. (2013) Insulin enhances metabolic capacities of cancer cells by dual regulation of glycolytic enzyme pyruvate kinase M2. Mol Cancer 12: 72. doi: 10.1186/1476-4598-12-72
[22]
Nemazanyy I, Espeillac C, Pende M, Panasyuk G (2013) Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression. Biochem Soc Trans 41: 917–922. doi: 10.1042/bst20130034
